

press release

OZEMPIC® is now listed on the Ontario provincial formulary for adults living with type 2 diabetes

MISSISSAUGA, ON – September 30, 2019 - Novo Nordisk is pleased to announce Ozempic® (semaglutide injection) is now publicly reimbursed in the province of Ontario. Ozempic® is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated alongside diet and exercise to improve glycemic control in adults with type 2 diabetes when metformin is inappropriate.¹ Ozempic® can also be used with metformin, sulfonylurea and basal insulin with metformin.¹

This announcement follows the regulatory approval of Ozempic® in January of 2018. Ozempic® was extensively studied in the SUSTAIN clinical trial program, which involved more than 8,000 adults with type 2 diabetes.¹ In the SUSTAIN program, Ozempic® was studied in combination with oral-antidiabetic agents and basal insulin.¹

"Having public access to effective treatment options is essential for people living with type 2 diabetes," explains Dr. Ronald Goldenberg, an endocrinologist affiliated with LMC Healthcare and North York General Hospital. "When left uncontrolled, diabetes can cause serious health problems that can negatively impact a person's quality of life. Being able to prescribe Ozempic®, which patients only need to take once a week, is an important step in helping to control the condition and reduce those risks."

"Type 2 diabetes impacts a person's quality of life, and if blood glucose levels remain high, it can also be life-threatening," says Vicky Chan, Vice President, Clinical Development, Medical and Regulatory Affairs, Novo Nordisk Canada. "We believe that Ozempic® has the potential to further improve the treatment of adults living with type 2 diabetes and we thank the Ontario government for their commitment to offering Canadians with type 2 diabetes innovative treatment options."

About Ozempic®

Ozempic® is a once-weekly analogue of human GLP-1 designed to mimic natural sugar metabolism by stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.¹ Ozempic® is available in a prefilled pen, based on the latest generation of Novo Nordisk prefilled devices.

Ozempic® had a well-tolerated profile across the SUSTAIN clinical trial program with the most common adverse events being generally mild to moderate gastrointestinal disorders, which diminished over time.¹

For information about Ozempic®, including important safety information, please visit NovoNordisk.ca or Ozempic.ca.

Ozempic® Coverage

Ozempic® is available through many private insurance plans and publicly reimbursed through the following national and provincial government-sponsored drug benefit programs:

- Non-Insured Health Benefits Program
- Alberta
- Prince Edward Island
- Ontario

About the SUSTAIN clinical trial program

SUSTAIN is a global clinical trial program for Ozempic® comprised of phase 3a clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.¹

Ozempic® demonstrated superior glycemic control versus other treatments: sitagliptin (SUSTAIN 2), dulaglutide (SUSTAIN 7) and canagliflozin (SUSTAIN 8).^{1,2,3} The SUSTAIN 7 trial included 1201 patients and was conducted to compare the efficacy and safety of Ozempic® 0.5mg and 1mg once weekly versus dulaglutide 0.75 mg and 1.5 mg once weekly (SUSTAIN 7).¹

Ozempic® demonstrated cardiovascular safety in SUSTAIN 6. In this trial, there was a 26% cardiovascular risk reduction in Ozempic® treated patients with type 2 diabetes at high cardiovascular risk, regardless of event history, gender or age.¹

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.ca, [Twitter](#) or [YouTube](#).

Further information

Media:

Kate Hanna

905-629-6612

kxyh@novonordisk.com

References

1. Ozempic® Product Monograph. Novo Nordisk Canada Inc. January 4, 2018.
2. Pratley R, et al. Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30024-X [Epub Ahead of Print].
3. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Prof Ildiko Lingavav, MD, Andrei-Mircea Catarig, MD, Juan P Frias, MD et al. Lancet Diabetes Endocrinol. September 17, 2019. DOI: [10.1016/S2213-8587\(19\)30311-0](https://doi.org/10.1016/S2213-8587(19)30311-0)